Tasmania supports both internationally significant wild fisheries and Australia’s largest aquaculture sector. For the sustainability of Tasmania’s aquaculture industry, aquaculture therapeutants play an important role in maintaining fish health and welfare.
The detection and presence of veterinary medicine residues in aquatic food products can affect market access and trade certification, even when food safety and environmental risks are low.
While the Australian Pesticides and Veterinary Medicines Authority (APVMA) regulates the approval and use of veterinary chemical products nationally, the Tasmanian Government has responsibilities for fisheries management, environmental regulation, biosecurity, managing the use of veterinary chemicals, food safety and the sustainable management of living marine resources.
The Aquaculture Therapeutant - Wild Fisheries Market Access Management Plan (the Plan) has been developed to provide a consistent, risk-based framework that protects market access and trade integrity, while supporting transparent decision-making and providing confidence to trading partners.
The Plan applies irrespective of the regulatory pathway under which an aquaculture therapeutant is used in the marine environment, freshwater or land-based salmon aquaculture facilities, recognising that residue management and market access considerations remain relevant regardless of whether treatment occurs under a product registration, permit, lawful off-label use or unauthorised release (for example, spillage from a feed barge).
The Plan was informed by the evidence generated through monitoring and research programs on florfenicol, a therapeutant applied to commercially farmed Atlantic salmon in southern Tasmania from November 2025 to March 2026.
The Plan does not endorse or approve the use of any therapeutant.
The Plan has now been finalised following consultation with relevant wild fisheries industry representatives.
The Plan is underpinned by an expectation that a wild fishery support package will be agreed and will be paid for by users of the therapeutant to the affected wild fishery industries.
Monitoring and research programs
Monitoring and research programs undertaken by the Department of Natural Resources and Environment Tasmania (NRE Tas), in collaboration with the Institute for Marine and Antarctic Science (IMAS), the Environment Protection Authority Tasmania (EPA) and industry, have significantly improved understanding of the occurrence and persistence of florfenicol residues in the marine environment and wild fisheries species.
This includes evidence that residue detections in wild fisheries species can occur at considerable distances from the treated aquaculture leases for several months following therapeutant dosing, and residue uptake varies between non-target wild fisheries species.
Findings
Sampling work is complete, and the interim results are presented in the
Summary of IMAS florfenicol results - July 2026 (PDF 188Kb)
Detections were found in abalone viscera and foot, rock lobster hepatopancreas (not tail meat) and other marine species. Complementary research is still underway.
These are interim findings and should be considered preliminary, until the full research program is complete.
The EPA conducted a separate environmental risk assessment and therapeutant monitoring program which assessed the distribution, persistence and potential environmental effects of florfenicol in water, sediment and scalefish species.
Antibiotic residue monitoring reports are published on the EPA website.
The results from both programs have been made available to relevant regulators and have informed fisheries management decision making.
Public Health
The Department of Health reviews each report of the antibiotic residue monitoring program. The Director of Public Health has advised that based on the monitoring in 2025 and 2026, the detections of low concentrations of florfenicol residue in some wild finfish posed no risk to human health.
Florfenicol residue was not detected at levels above the limit of reporting in water samples collected by Public Health from recognised recreational water use sites during several treatment events.
For more information, visit the Department of Health website.
More information
We provide more information on our Salmon web page and our Fish Health web page.
Previous statements and notices:
Regulator Statement - 9 September 2026 (PDF 121Kb)
Regulator Notice - 18 February 2026 (PDF 147Kb)
Regulator Notice - 7 November 2025 (PDF 342Kb)
More information is also available on our Frequently Asked Questions web page.